MP0250-a dual inhibitor of VEGF and HGF - plus bortezomib plus dexamethasone in a phase 2 open-label, single-arm, multicenter trial in patients with refractory and relapsed multiple myeloma (RRMM)

被引：0
|
作者：
Raab, M. S. [1 ]
Ria, R. [2 ]
Schlenzka, J. [1 ]
Krahnke, T. [3 ]
Haunschild, J. [4 ]
Herrmann, F. [4 ]
Fiedler, U. [5 ]
Dawson, K. [6 ]
Stumpp, M. T. [7 ]
Mehr, K. Tadjalli [4 ]
Harstrick, A. [4 ]
Vacca, A. [2 ]
Goldschmidt, H. [1 ]
机构：
[1] Heidelberg Univ Hosp, Dept Haematol Oncol & Rheumatol, Heidelberg, Germany
[2] Univ Bari, Med Sch, Dept Biomed Sci & Human Oncol, Sect Internal Med, Bari, Italy
[3] Gogitars GmbH, Biostat, Heidelberg, Germany
[4] Mol Partners AG, Clin Dev, Schlieren, Switzerland
[5] Mol Partners AG, Preclin, Schlieren, Switzerland
[6] Mol Partners AG, Preclin Toxicol, Schlieren, Switzerland
[7] Mol Partners AG, CSO, Schlieren, Switzerland
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1041TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [1] PRELIMINARY DATA OF THE ONGOING OPEN-LABEL, SINGLE-ARM PHASE II STUDY OF MP0250 IN COMBINATION WITH BORTEZOMIB plus DEXAMETHASONE IN PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA
    Goldschmidt, H.
    Raab, M. S.
    Duerig, J.
    Szarejko, M.
    Jurczyszyn, A.
    Grzasko, N.
    Vacca, A.
    Bringhen, S.
    D'Agostino, M.
    Gamberi, B.
    Haunschild, J.
    Hermann, F.
    Fiedler, U.
    Dawson, K.
    Harstrick, A.
    Acosta, J.
    Schreder, M.
    Knop, S.
    HAEMATOLOGICA, 2018, 103 : 13 - 13
  • [2] Efficacy and safety of generic pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma: a multicenter, open-label, single-arm trial
    Zhou, Huixing
    Wang, Yafei
    Chen, Jiao
    He, Aili
    Jin, Jie
    Lu, Quanyi
    Zhao, Ying
    Li, Junjun
    Hou, Ming
    Su, Liping
    Lai, Xun
    Wang, Wei
    Liu, Lihong
    Ma, Yanping
    Gao, Da
    Lai, Wenhong
    Zhou, Xin
    Jing, Hongmei
    Zhang, Jinqiao
    Yang, Wei
    Ran, Xuehong
    Lin, Congmeng
    Hao, Jianping
    Xiao, Taiwu
    Huang, Zhenqian
    Zhu, Zhigang
    Wang, Qing
    Fang, Baijun
    Wang, Binghua
    Song, Yanping
    Cai, Zhen
    Liu, Bo
    Zhu, Yanan
    Yang, Xinai
    Kang, Xiaoyan
    Li, Juan
    Chen, Wenming
    ANNALS OF HEMATOLOGY, 2024, 103 (03) : 855 - 868
  • [3] Efficacy and safety of generic pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma: a multicenter, open-label, single-arm trial
    Huixing Zhou
    Yafei Wang
    Jiao Chen
    Aili He
    Jie Jin
    Quanyi Lu
    Ying Zhao
    Junjun Li
    Ming Hou
    Liping Su
    Xun Lai
    Wei Wang
    Lihong Liu
    Yanping Ma
    Da Gao
    Wenhong Lai
    Xin Zhou
    Hongmei Jing
    Jinqiao Zhang
    Wei Yang
    Xuehong Ran
    Congmeng Lin
    Jianping Hao
    Taiwu Xiao
    Zhenqian Huang
    Zhigang Zhu
    Qing Wang
    Baijun Fang
    Binghua Wang
    Yanping Song
    Zhen Cai
    Bo Liu
    Yanan Zhu
    Xinai Yang
    Xiaoyan Kang
    Juan Li
    Wenming Chen
    Annals of Hematology, 2024, 103 : 855 - 868
  • [4] Phase 1 open-label study of panobinostat, lenalidomide, bortezomib plus dexamethasone in relapsed and relapsed/refractory multiple myeloma
    Laubach, Jacob P.
    Tuchman, Sascha A.
    Rosenblatt, Jacalyn M.
    Mitsiades, Constantine S.
    Colson, Kathleen
    Masone, Kelly
    Warren, Diane
    Redd, Robert A.
    Grayson, Dena
    Richardson, Paul G.
    BLOOD CANCER JOURNAL, 2021, 11 (02)
  • [5] Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of Panobinostat in Combination with Bortezomib and Dexamethasone in Japanese Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma
    Suzuki, Kenshi
    Sunami, Kazutaka
    Matsumoto, Morio
    Maki, Akio
    Shimada, Fumika
    Suzuki, Kazuyuki
    Shimizu, Kazuyuki
    ACTA HAEMATOLOGICA, 2021, 144 (03) : 264 - 274
  • [6] A phase 2, open-label, multicenter study of ixazomib plus lenalidomide and dexamethasone in adult Japanese patients with relapsed and/or refractory multiple myeloma
    Shinsuke Iida
    Tohru Izumi
    Takuya Komeno
    Yasuhito Terui
    Takaaki Chou
    Takashi Ikeda
    Deborah Berg
    Shinichi Fukunaga
    Kenkichi Sugiura
    Makoto Sasaki
    International Journal of Clinical Oncology, 2022, 27 : 224 - 233
  • [7] A phase 2, open-label, multicenter study of ixazomib plus lenalidomide and dexamethasone in adult Japanese patients with relapsed and/or refractory multiple myeloma
    Iida, Shinsuke
    Izumi, Tohru
    Komeno, Takuya
    Terui, Yasuhito
    Chou, Takaaki
    Ikeda, Takashi
    Berg, Deborah
    Fukunaga, Shinichi
    Sugiura, Kenkichi
    Sasaki, Makoto
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (01) : 224 - 233
  • [8] A MULTICENTER, SINGLE-ARM, OPEN-LABEL SAFETY AND QUALITY OF LIFE STUDY OF LENALIDOMIDE PLUS DEXAMETHASONE IN PREVIOUSLY TREATED PATIENTS WITH MULTIPLE MYELOMA
    Yong, K.
    Alegre Amor, A.
    Browne, P.
    Cavenagh, J.
    Dodds, T.
    Greil, R.
    Horvath, N.
    Ludwig, H.
    O'Dwyer, M.
    Oriol Rocafiguera, A.
    Prince, M.
    Taylor, K.
    Knight, R.
    Rosettani, B.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 392 - 392
  • [9] A phase 3 randomized, controlled, open-label study of selinexor, bortezomib, and dexamethasone (SVd) versus bortezomib and dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma (RRMM).
    Delimpasi, Sosana
    Pour, Ludek
    Auner, Holger W.
    Dimopoulos, Meletios A.
    Rappaport, Alon
    Fortin, Lisa
    Shah, Jatin J.
    Shacham, Sharon
    Kauffman, Michael G.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [10] Venetoclax plus cytarabine and azacitidine in relapsed/refractory AML: An open-label, single-arm, phase 2 study
    You, Liangshun
    Liu, Yi
    Mai, Wenyuan
    Xie, Wanzhuo
    Zhou, De
    Mao, Liping
    Chen, Lili
    Zhou, Xinping
    Ma, Liya
    Zheng, Xiaolong
    Wei, Juying
    Lou, Yinjun
    Ye, Xingnong
    Tong, Hongyan
    Jin, Jie
    Meng, Haitao
    EUROPEAN JOURNAL OF CANCER, 2024, 202
12345